Uncategorized

Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific

Published

on

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version